Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.
Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J; International Breast Cancer Study Group Trials I through VII. Wallgren A, et al. Among authors: forbes jf. J Clin Oncol. 2003 Apr 1;21(7):1205-13. doi: 10.1200/JCO.2003.03.130. J Clin Oncol. 2003. PMID: 12663706 Clinical Trial.
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Colleoni M, et al. Among authors: forbes jf. J Clin Oncol. 2011 Mar 20;29(9):1117-24. doi: 10.1200/JCO.2010.31.6455. Epub 2011 Feb 14. J Clin Oncol. 2011. PMID: 21321298 Free PMC article. Clinical Trial.
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT. Ewertz M, et al. Among authors: forbes jf. J Clin Oncol. 2012 Nov 10;30(32):3967-75. doi: 10.1200/JCO.2011.40.8666. Epub 2012 Oct 8. J Clin Oncol. 2012. PMID: 23045588 Free PMC article. Clinical Trial.
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Colleoni M, et al. Among authors: forbes jf. J Clin Oncol. 2016 Mar 20;34(9):927-35. doi: 10.1200/JCO.2015.62.3504. Epub 2016 Jan 19. J Clin Oncol. 2016. PMID: 26786933 Free PMC article.
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
International Breast Cancer Study Group; Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS. International Breast Cancer Study Group, et al. Among authors: forbes jf. J Clin Oncol. 2006 Jan 20;24(3):337-44. doi: 10.1200/JCO.2005.01.5784. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344321 Clinical Trial.
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS; International Breast Cancer Study Group Trial VIII. Bernhard J, et al. Among authors: forbes jf. J Clin Oncol. 2007 Jan 20;25(3):263-70. doi: 10.1200/JCO.2005.04.5393. Epub 2006 Dec 11. J Clin Oncol. 2007. PMID: 17159194 Clinical Trial.
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. Karlsson P, et al. Among authors: forbes jf. J Clin Oncol. 2007 May 20;25(15):2019-26. doi: 10.1200/JCO.2006.09.8152. Epub 2007 Apr 9. J Clin Oncol. 2007. PMID: 17420511
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Pagani O, et al. Among authors: forbes jf. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25. Breast Cancer Res Treat. 2009. PMID: 18953651 Free PMC article. Clinical Trial.
219 results